Market Research Logo

ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review

ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides

- you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company’s lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc Key Recent Developments

May 04,2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
Apr 25,2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
Feb 09,2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results
Nov 03,2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
Jul 28,2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
ImmunoGen Inc - Key Facts
ImmunoGen Inc - Key Employees
ImmunoGen Inc - Key Employee Biographies
ImmunoGen Inc - Major Products and Services
ImmunoGen Inc - History
ImmunoGen Inc - Company Statement
ImmunoGen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
ImmunoGen Inc - Business Description
ImmunoGen Inc - Corporate Strategy
ImmunoGen Inc - SWOT Analysis
SWOT Analysis - Overview
ImmunoGen Inc - Strengths
ImmunoGen Inc - Weaknesses
ImmunoGen Inc - Opportunities
ImmunoGen Inc - Threats
ImmunoGen Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ImmunoGen Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results
Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results
May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results
Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016
Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
ImmunoGen Inc, Key Facts
ImmunoGen Inc, Key Employees
ImmunoGen Inc, Key Employee Biographies
ImmunoGen Inc, Major Products and Services
ImmunoGen Inc, History
ImmunoGen Inc, Subsidiaries
ImmunoGen Inc, Key Competitors
ImmunoGen Inc, Ratios based on current share price
ImmunoGen Inc, Annual Ratios
ImmunoGen Inc, Annual Ratios (Cont...1)
ImmunoGen Inc, Interim Ratios
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ImmunoGen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
ImmunoGen Inc, Performance Chart (2013 - 2017)
ImmunoGen Inc, Ratio Charts
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report